Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era

Anticancer Research

Volumn 34, Issue 5, 2014, Pages 2405-2412

  Abern, Michael R ^a   Scosyrev, Emelian ^b   Tsivian, Matvey ^c   Messing, Edward M ^b   Polascik, Thomas J ^c   Dudek, Arkadiusz Z ^d  

^a Department of Urology ^*  (India)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Cytoreductive nephrectomy; Renal cell carcinoma; Targeted therapy; Tyrosine kinase inhibitor

Indexed keywords

PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CANCER EPIDEMIOLOGY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; FOLLOW UP; HUMAN; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; NEPHRECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIMARY TUMOR; SURVIVAL RATE; SYSTEMIC THERAPY; AGED; CANCER REGISTRY; CYTOREDUCTIVE NEPHRECTOMY; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; KIDNEY TUMOR; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PROPORTIONAL HAZARDS MODEL; TARGETED THERAPY; TREATMENT OUTCOME;

CYTOREDUCTIVE NEPHRECTOMY; RENAL CELL CARCINOMA; TARGETED THERAPY; TYROSINE KINASE INHIBITOR;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEPHRECTOMY; PROPORTIONAL HAZARDS MODELS; SEER PROGRAM; TREATMENT OUTCOME;

EID: 84902963828     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Howlader N, Noone A, Krapcho M, Neyman N, Aminou R, Altekruse S, Kosary C, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner M, Lewis D, Chen H, Feuer E and Cronin K: SEER Cancer Statistics Review 2012 January 2013.
2. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A and Ward E: Cancer treatment and survivorship statistics, 2012. CA: A Cancer Journal for Clinicians 62(4): 220-241, 2012.
3. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H and Crawford ED: Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171(3): 1071-1076, 2004.
4. Oosterwijk E, Rathmell WK, Junker K, Brannon AR, Pouliot F, Finley DS, Mulders PF, Kirkali Z, Uemura H and Belldegrun A: Basic research in kidney cancer. Eur Urol 60(4): 622-633, 2011.
5. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L and Motzer RJ: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22): 2271-2281, 2007.
6. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM and Figlin RA: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2): 115-124, 2007.
7. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER∗Stat Database: Incidence-SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2011 Sub (1973-2009 varying)-Linked To County Attributes-Total U.S., 1969-2010 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2012, based on the November 2011 submission. 2013.
8. AJCC Cancer Staging Manual1/1/2014: Available from: https://cancerstaging.org/references-tools/deskreferences/Documents/AJCC6thEdCancerStagingManualPart1.pdf.
9. You D, Jeong IG, Ahn JH, Lee DH, Lee JL, Hong JH, Ahn H and Kim CS: The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy. J Urol 185(1): 54-59, 2011.
10. Venner P: Cytoreductive nephrectomy: a treatment of the past. Can Urol Assoc J 4(1): 68-69, 2010.
11. Tsao CK, Small AC, Moshier EL, Gartrell BA, Wisnivesky JP, Sonpavde G, Godbold JH, Palese MA, Hall SJ, Oh WK and Galsky MD: Trends in the use of cytoreductive nephrectomy in the United States. Clin Genitourin Cancer 10(3): 159-163, 2012.
12. Patil S, Manola J, Elson P, Negrier S, Escudier B, Eisen T, Atkins M, Bukowski R and Motzer RJ: Improvement in overall survival of patients with advanced renal cell carcinoma: prognostic factor trend analysis from an international data set of clinical trials. J Urol 188(6): 2095-2100, 2012.
13. Aizer AA, Urun Y, McKay RR, Kibel AS, Nguyen PL and Choueiri TK: Cytoreductive nephrectomy in patients with metastatic non-clear cell renal cell carcinoma. BJU Int, 2013.
14. Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, Zhou M, Rini BI, Bukowski RM and Escudier B: Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 26(1): 127-131, 2008.
15. Zini L, Capitanio U, Perrotte P, Jeldres C, Shariat SF, Arjane P, Widmer H, Montorsi F, Patard JJ and Karakiewicz PI: Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. Urology 73(2): 342-346, 2009.
16. Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC and Blute ML: Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 117(13): 2873-2882, 2011.
17. Pierorazio PM, McKiernan JM, McCann TR, Mohile S, Petrylak D and Benson MC: Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed. BJU Int 100(4): 755-759, 2007.
18. Cost NG, Delacroix SE Jr., Sleeper JP, Smith PJ, Youssef RF, Chapin BF, Karam JA, Culp S, Abel EJ, Brugarolas J, Raj G V, Sagalowsky AI, Wood CG and Margulis V: The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol 59(6): 912-918, 2011.
19. Abel EJ, Carrasco A, Culp SH, Matin SF, Tamboli P, Tannir NM and Wood CG: Limitations of preoperative biopsy in patients with metastatic renal cell carcinoma: comparison to surgical pathology in 405 cases. BJU Int 110(11): 1742-1746, 2012.
20. Kroon BK, de Bruijn R, Prevoo W, Horenblas S, Powles T and Bex A: Probability of downsizing primary tumors of renal cell carcinoma by targeted therapies is related to size at presentation. Urology 81(1): 111-115, 2013.
21. Abel EJ, Culp SH, Tannir NM, Matin SF, Tamboli P, Jonasch E and Wood CG: Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol 59(1): 10-15, 2011.
22. Lara PN, Jr., Tangen CM, Conlon SJ, Flanigan RC and Crawford ED: Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949. J Urol 181(2): 512-516; discussion 6-7, 2009.
23. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A and Ferrara J: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17(8): 2530-2540, 1999.
24. Motzer RJ, Bukowski RM, Figlin RA, Hutson TE, Michaelson MD, Kim ST, Baum CM and Kattan MW: Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 113(7): 1552-1558, 2008.
25. Kutikov A, Uzzo RG, Caraway A, Reese CT, Egleston BL, Chen DY, Viterbo R, Greenberg RE, Wong YN, Raman JD and Boorjian SA: Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU Int 106(2): 218-223, 2010.
26. Capitanio U, Abdollah F, Matloob R, Salonia A, Suardi N, Briganti A, Carenzi C, Rigatti P, Montorsi F and Bertini R: Effect of number and location of distant metastases on renal cell carcinoma mortality in candidates for cytoreductive nephrectomy: implications for multimodal therapy. Int J Urol Association 20(6): 572-579, 2013.
27. Margulis V, Shariat SF, Rapoport Y, Rink M, Sjoberg DD, Tannir NM, Abel EJ, Culp SH, Tamboli P and Wood CG: Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Eur Urol 63(5): 947-952, 2013.